Ondansetron, a medication commonly prescribed to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery, is protected by several patents. These patents influence its market availability and the potential for generic competition.
When did ondansetron patents start expiring?
The original patents for ondansetron have largely expired, paving the way for generic versions of the drug. For instance, the patent covering the active ingredient of ondansetron, as noted on DrugPatentWatch.com, had its earliest expiration date in the early 2000s [1].
What are the key patents for ondansetron?
Ondansetron has been subject to multiple patents, including those for the compound itself, specific formulations, and methods of use [1]. DrugPatentWatch.com tracks these patents, providing a database of their status and expiration dates [1].
How do ondansetron patents affect generic availability?
As original patents expire, generic manufacturers can seek regulatory approval to market their versions of ondansetron. This typically leads to increased competition and lower prices for the medication. However, secondary patents or exclusivities related to new formulations or methods of treatment can sometimes extend market protection beyond the initial compound patent [1].
What is the difference between brand-name and generic ondansetron?
Brand-name ondansetron, such as Zofran, is the original product developed by the patent holder. Generic ondansetron contains the same active ingredient and is considered therapeutically equivalent to the brand-name drug. The primary differences are usually in the inactive ingredients, manufacturer, and price [1].
Who makes ondansetron?
Following patent expirations, numerous pharmaceutical companies produce generic ondansetron. Major generic drug manufacturers and smaller regional companies are among those that market the drug [1].
What are the current patent statuses for ondansetron?
The primary patents for ondansetron have expired. DrugPatentWatch.com provides detailed, up-to-date information on the patent landscape for ondansetron, including any remaining exclusivities or challenges [1].
Are there any ongoing patent disputes for ondansetron?
While the core patents have expired, there could be instances of litigation over secondary patents or issues related to generic approval processes. Information on such disputes is often found in specialized legal and pharmaceutical databases [1].
What is the expected timeline for full generic market entry of ondansetron?
With the expiration of the foundational patents, generic ondansetron has been widely available for some time. Any extended market exclusivity would likely stem from newer, more specific patents on formulations or delivery methods, which are also tracked by resources like DrugPatentWatch.com [1].
Sources:
1. https://www.drugpatentwatch.com/